The present invention provides a lung cancer therapeutic agent for treating lung cancer patients, particularly NSCLC patients resistant to EGFR-TKI, and a predictive testing method for effectiveness of lung cancer patient treatment. As a result of earnest study on therapeutic agents for lung cancer patients with an optimal combination of HDAC inhibitor and EGFR-TKI, "When BIM in a sample derived from an NSCLC patient resistant to EGFR-TKI is non-wild type, EGFR-TKI alone has low therapeutic effectiveness but it is effective for the treatment of administration of a therapeutic agent for lung cancer patients combining JNJ-26481585 and EGFR-TKI or administration of a therapeutic agent for lung cancer patients combining CUDC-101 and EGFR-TKI It is high in sex "and completed the present invention.肺癌患者、特に、EGFR-TKIに耐性を有するNSCLC患者の治療の肺癌治療剤及び肺癌患者治療の有効性の予測検査方法を提供する。 HDAC阻害剤とEGFR-TKIの最適な組み合わせの肺癌患者用治療剤を鋭意検討した結果、「EGFR-TKIに耐性を有するNSCLC患者由来のサンプル中のBIMが非野生型である場合には、EGFR-TKI単独投与は治療の有効性が低いが、JNJ-26481585とEGFR-TKIを組み合わせた肺癌患者用治療剤又はCUDC-101とEGFR-TKIを組み合わせた肺癌患者用治療剤の投与の治療の有効性が高いこと」を見出し、本発明を完成した。
